2,438 results on '"Leiter, Lawrence A."'
Search Results
402. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
403. Bempedoic Acid Efficacy and Safety in High CVD Risk Patients Treated With or Without Ezetimibe: Pooled Analysis of 4 Phase 3 Clinical Trials†
404. Efficacy and Safety of Bempedoic Acid in Elderly Patients: Pooled Analyses from Phase 3 Trials
405. 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME
406. 403-P: Impact of Diabetes-Related Factors and Background Antihyperglycemic Therapy on the Efficacy and Safety of Ticagrelor Added to Aspirin: Insights from the THEMIS Trial
407. 185-OR: Efficacy and Safety of Bempedoic Acid in Patients with Diabetes, Prediabetes, and Normoglycemia: Analysis of Pooled Patient-Level Data from Four Phase 3 Clinical Trials
408. 303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial
409. 1021-P: HbA1c Levels and Rates of Hypoglycemia with Insulin Degludec U200 and Insulin Glargine U300 Stratified by Renal Function Subgroups: Post Hoc Analysis from the CONCLUDE Trial
410. 1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58
411. Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial
412. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
413. Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children
414. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study
415. Latest Evidence on Sulfonylureas: What’s New?
416. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
417. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
418. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
419. Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes
420. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
421. OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind
422. Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial
423. The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial
424. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus
425. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
426. EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL
427. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial
428. INCLISIRAN AND CARDIOVASCULAR OUTCOMES: ANALYSES FROM ORION-11
429. BEMPEDOIC ACID EFFICACY AND SAFETY IN HIGH CVD RISK PATIENTS TREATED WITH OR WITHOUT EZETIMIBE: POOLED ANALYSIS OF 4 PHASE 3 CLINICAL TRIALS
430. EFFECT OF INCLISIRAN ON LDL-C REDUCTION ACROSS DIFFERENT BACKGROUND LIPID LOWERING TREATMENTS: ANALYSES FROM ORION-11
431. A LEADER in the management of type 2 diabetes and cardiorenal disease
432. EVALUATION OF LDL-C REDUCTIONS BY SIRNA TREATMENT WITH INCLISIRAN IN PATIENTS WITH DIABETES MELLITUS, METABOLIC SYNDROME OR NEITHER
433. GOAL Canada: Physician Education and Support Can Improve Patient Management
434. 6 MONTHLY INCLISIRAN AND ATHEROGENIC LIPOPROTEIN REDUCTIONS IN ORION-11
435. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
436. Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab
437. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
438. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
439. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets
440. Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data
441. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
442. Adding monounsaturated fatty acids to a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia
443. Patient Age, Ethnicity, Medical History, and Risk Factor Profile, but Not Drug Insurance Coverage, Predict Successful Attainment of Glycemic Targets: Time 2 Do More Quality Enhancement Research Initiative (T2DM QUERI)
444. 22. Long-Term Safety and Efficacy of Dapagliflozin in Patients with T2DM and Cardiovascular Disease (106-OR)
445. Important Food Sources of Fructose‐Containing Sugars and Incident Hypertension: A Systematic Review and Dose‐Response Meta‐Analysis of Prospective Cohort Studies
446. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study
447. Relation of Total Sugars, Sucrose, Fructose, and Added Sugars With the Risk of Cardiovascular Disease
448. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease
449. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
450. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.